MAILPAN (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients.
The project proposal of a 36-month duration intends to bring the most modern and up to date improvements that the bioartificial pancreas still needs and can receive such as to enhance cells survival inside the device by formulating a new adapted cell culture medium, to further lower the rejection risk by studying the biocompatibility and anti-inflammatory mechanisms, to test the prototype in primates, and to validate its further use in humans.
a leader in the research and development of a bioartificial pancreas, a minimally invasive cellular transplant for the treatment of insulin-dependent diabetes mellitus, has obtained exclusive rights for diabetes cell therapy from the University of Texas to United States Patent Number 5,529,914, issued on June 25, 1996.
NYSE: GRA) today announced that it will commence human Phase I clinical trials of its BioArtificial Pancreas to determine the safety and tolerability of the implant in diabetic patients.
Our ultimate goal is to demonstrate that the BioArtificial Pancreas can help patients suffering from insulin-dependent diabetes lead more normal lives and minimize some of the complications associated with diabetes," said Dr.